首页> 外文期刊>Nucleic Acids Research >Tissue-specific chromatin structure of the phenobarbital-responsive unit and proximal promoter of CYP2B1/2 and modulation by phenobarbital.
【24h】

Tissue-specific chromatin structure of the phenobarbital-responsive unit and proximal promoter of CYP2B1/2 and modulation by phenobarbital.

机译:苯巴比妥反应单元的组织特异性染色质结构和CYP2B1 / 2的近端启动子以及苯巴比妥的调节。

获取原文
获取原文并翻译 | 示例
           

摘要

Phenobarbital induction of transcription of CYP2B genes is mediated by an enhancer, termed a phenobarbital responsive unit (PBRU), approximately 2000 bp 5' of the transcription start site. To further delineate the mechanism of phenobarbital induction, protein binding in native chromatin and the nucleosomal structure of the PBRU and proximal promoter were examined in liver and kidney, in which the CYP2B1/2 genes are expressed and not expressed, respectively. Protein binding to the PBRU in kidney chromatin was not detected even though in vitro DNase I footprints were not detectably different with nuclear extracts from liver and kidney. Likewise, protein binding to regulatory motifs was not detected in the proximal promoter region in kidney chromatin. In liver chromatin, however, DNase I hypersensitivity and partial protection of the regulatory motifs from DNase I digestion or reaction with dimethyl sulfate was observed and phenobarbital treatment increased the hypersensitivity but only modestly affected protection. Low resolution Southern analysis of micrococcal nuclease-digested chromatin from untreated rats revealed micrococcal nuclease hypersensitive regions in the proximal promoter and PBRU regions in liver, but not in kidney. Phenobarbital treatment increased hyper-sensitivity in liver in both regions. Micrococcal nuclease hypersensitivity in the PBRU was largely restricted to a linker region between phased nucleosomes while in the proximal promoter hypersensitivity extended over approximately 200 bp suggesting disruption of a nucleosome in this region. These data indicate that in liver phenobarbital treatment substantially alters protein binding to regulatory motifs in the PBRU, while not greatly affecting such binding in the proximal promoter, and substantially alters chromatin structure in both regions, presumably as a result of chromatin modifying factors recruited to the PBRU. In the kidney, chromatin is probably in a closed conformation that prevents binding of regulatory factors.
机译:CYP2B基因转录的苯巴比妥诱导是通过增强子介导的,该增强子被称为苯巴比妥反应单位(PBRU),大约转录起始位点的5'bp。为了进一步描述苯巴比妥诱导的机制,在肝脏和肾脏中检测了天然染色质中的蛋白质结合以及PBRU和近端启动子的核小体结构,其中分别表达和不表达CYP2B1 / 2基因。即使体外DNase I足迹与肝脏和肾脏的核提取物没有明显差异,也未检测到与肾脏染色质中的PBRU结合的蛋白质。同样,在肾脏染色质的近端启动子区域也未检测到与调控基序结合的蛋白质。然而,在肝脏染色质中,观察到DNase I超敏性和对调节基序的部分保护,以防止DNase I消化或与硫酸二甲酯反应,苯巴比妥治疗可增加超敏性,但仅适度影响了保护。对未经处理的大鼠进行的微球菌核酸酶消化的染色质的低分辨率Southern分析表明,肝脏近端启动子和PBRU区域中微球菌核酸酶超敏区域,但肾脏中无。苯巴比妥治疗增加了这两个地区的肝脏超敏反应。 PBRU中的微球菌核酸酶超敏性主要限于相控核小体之间的连接子区域,而近端启动子中的超敏性延伸超过约200 bp,表明该区域中的核小体被破坏。这些数据表明,在肝苯巴比妥治疗中,实质上改变了蛋白质与PBRU中调控基序的结合,而并未极大地影响近端启动子中的这种结合,并且实质上改变了两个区域的染色质结构,这可能是由于向细胞中募集了染色质修饰因子。 PBRU。在肾脏中,染色质可能处于封闭状态,阻止了调节因子的结合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号